Oleocanthal functional food products for breast cancer recurrence control
Award amount
$454,755Program and phase
STTR · Phase IAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Oleolive, Inc.
- Proposal award date
- 2020-06-01
- Contract end date
- 2022-05-31
- UEI
- DSBCG7NS87J3
- Solicitation number
- PA18-837
- Topic code
- 102
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis
- Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease
- Chemosensitization of Glioblastoma by Propentofylline
- Open Call for Innovative Defense-Related Dual-Purpose Technologies/Solutions with a Clear Air Force Stakeholder Need
- Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimer’s Disease
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer
Research funding history
8 SBIR/STTR records share this UEI (2018–2025). Reported award amounts total $5,248,395. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense